No record found
capitalstake.com. Provided by * Returns not adjusted for payouts
^The historical stock prices have been adjusted to reflect stock splits to ensure comparability over time.
Company Profile
Citi Pharma Limited was incorporated as a private limited company in Pakistan under the Repealed Companies Ordinance, 1984 on October 08, 2012. The principal activity of the company is manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. The company was converted into public unlisted company with effect from October 13, 2020. The Company was listed on Pakistan Stock Exchange on July 09, 2021.
| Rizwan Ahmad | CEO |
| Nadeem Amjad | Chairperson |
| Muhammad Rasheed Alam | Company Secretary |
F.D Registrar Services (Pvt.) Ltd.
Aslam Malik & Co. Chartered Accountants
June
Equity Profile
Announcements
| Date | Title | Document |
|---|---|---|
| Nov 2, 2026 | Transmission of Quarterly Report for the Period Ended 30 September 2026 | View PDF |
| Nov 2, 2026 | Financial Results for the Quarter Ended 30 September 2026 | View PDF |
| Oct 7, 2026 | Transmission of Annual Report for the Year Ended 30 June 2026 | View PDF |
| Oct 5, 2026 | Financial Results for the Year Ended 30 June 2026 | View PDF |
| Apr 30, 2026 | Transmission of Quarterly Report for the Period Ended 31st March 2026 | View PDF |
| Date | Title | Document |
|---|---|---|
| Oct 30, 2026 | Board Meeting In Progress | View |
| Oct 28, 2026 | Certified true copy of the resolutions passed in the Annual General Meeting of the Company | View PDF |
| Oct 23, 2026 | Board Meeting | View PDF |
| Oct 7, 2026 | Notice of Annual General Meeting - Post Publication | View PDF |
| Oct 6, 2026 | Notice of Annual General Meeting (Prior to Publication) | View PDF |
| Date | Title | Document |
|---|---|---|
| Oct 30, 2026 | Material Information | View PDF |
| Oct 26, 2026 | Change of Chief Financial Officer | View PDF |
| Oct 19, 2026 | Material Information | View PDF |
| Aug 10, 2026 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
| Aug 7, 2026 | Chief Financial Officer | View PDF |
Financials
All numbers in thousands (000's) except EPS
| 2026 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Sales | 14,004,608 | 13,153,521 | 12,409,239 | 12,396,983 |
| Profit after Taxation | 782,597 | 892,039 | 833,464 | 657,984 |
| EPS | 3.43 | 3.90 | 3.65 | 2.88 |
| Q1 2027 | Q3 2026 | Q2 2026 | Q1 2026 | |
|---|---|---|---|---|
| Sales | 3,363,459 | 3,084,746 | 4,332,566 | 3,370,247 |
| Profit after Taxation | 233,227 | 275,415 | 404,334 | 203,691 |
| EPS | 1.02 | 1.21 | 1.77 | 0.89 |

Ratios
| 2026 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Gross Profit Margin (%) | 17.49 | 15.34 | 12.78 | 12.16 |
| Net Profit Margin (%) | 5.59 | 6.78 | 6.72 | 5.31 |
| EPS Growth (%) | (12.05) | 6.85 | 26.74 | |
| PEG | (1.88) | 3.14 | 0.29 |








Feedback
Terms of Use
https://www.psx.com.pk